Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Neoplasms 3Colorectal Neoplasms 2Breast Neoplasms 2Solid Tumors 1Ovarian Neoplasms 1Multiple Myeloma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × dalotuzumab × Clear all
NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Merck Sharp & Dohme LLC

Phase 1 Terminated
47 enrolled 12 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00925015 2018-08-15

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Merck Sharp & Dohme LLC

Phase 1 Completed
20 enrolled 30 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡